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Abstract
Background: The expression status of apoptotic regulators, such as caspases and inhibitors of apoptosis proteins
(IAPs), could reflect the aggressiveness of tumors and, therefore, could be useful as prognostic markers. We explored
the associations between tumor expression of caspases and IAPs and clinicopathological features of prostate cancer –
clinical and pathological T stage, Gleason score, preoperative serum PSA levels, perineural invasion, lymph node
involvement, surgical margin status and overall survival – and evaluated its capability to predict biochemical
progression after radical prostatectomy.
Methods: Protein expression of caspases (procaspase-8, cleaved caspase-8, procaspase-3, cleaved caspase-3,
caspase-7 and procaspase-9) and IAPs (cIAP1/2, cIAP2, NAIP, Survivin and XIAP) was analyzed by immunohistochemistry
in radical prostatectomy samples from 84 prostate cancer patients. Spearman’s test, Kaplan-Meier curves, and univariate
and multivariate Cox proportional hazard regression analysis were performed.
Results: cIAP1/2, cIAP2, Survivin, procaspase-8, cleaved caspase-8, procaspase-3 and caspase-7 expression correlated
with at least one clinicopathological feature of the disease. Patients negative for XIAP, procaspase-3 or cleaved
caspase-3 had a significantly worse prognosis. Of note, XIAP, procaspase-3 and cleaved caspase-3 were predictors
of biochemical progression independent of Gleason score and pathological T stage.
Conclusions: Our results indicate that alterations in the expression of IAPs and caspases contribute to the
malignant behavior of prostate tumors and suggest that tumor expression of XIAP, procaspase-3 and cleaved
caspase-3 may help to identify prostate cancer patients at risk of progression.
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Background
There are several well-established markers that predict
prostate cancer progression after radical prostatectomy,
including Gleason grade, pathological stage and preopera-
tive serum PSA [1]. Identification of biological factors that
better reflect aggressiveness of tumors could help to
improve the prediction capability of the existing makers.
Apoptosis is a type of programmed cell death that
ensures the elimination of unnecessary or potentially
harmful cells. Caspases constitute a family of cysteine
proteases involved in the initiation and execution of the
apoptotic program. The apoptotic cascades entail the
activation by proteolysis of initiator caspases (caspase-
2, −8, −9 and −10), which in turn proteolyze and acti-
vate executioner caspases (caspase-3, −6 and −7) [2].
There are two major apoptotic pathways: the extrinsic
and the intrinsic (or mitochondrial) apoptotic pathways.
These apoptotic pathways converge in the activation of
executioner caspases, which proteolyze a plethora of
substrates ultimately leading to the death of the cell [3].
Evasion of apoptosis, a characteristic of tumor cells,
occurs by alteration in the levels and functions of apop-
tosis regulators [4]. In this regard, loss of expression of
caspases is frequent in several human malignancies, in-
cluding prostate cancer [5], and has been linked in some
cases to poor prognosis [6, 7] and resistance to cell
death induced by death receptors and chemotherapeutic
compounds [8, 9]. Other important apoptosis regulators
frequently altered in human cancers are the inhibitors of
apoptosis proteins (IAPs). The IAP family in humans
comprises eight members: NAIP (neuronal apoptosis
inhibitory protein), XIAP (X-linked inhibitor of apop-
tosis protein), ILP2 (IAP-like protein 2), cIAP1 (cellular
IAP 1), cIAP2, BRUCE (Baculoviral IAP repeat contain-
ing ubiquitin-conjugating enzyme), Survivin and Livin
(ML-IAP), characterized by containing at least one
baculoviral IAP repeat (BIR) domain [10]. IAPs are able
to inhibit apoptosis induced by a variety of stimuli
through different mechanisms, including direct inhibition
of caspases (XIAP), sequestration of pro-apoptotic mole-
cules such as SMAC/DIABLO (cIAP1/2, Survivin, Livin),
ubiquitin-mediated degradation and non-degradative in-
activation of caspases (cIAP1/2, XIAP), and activation of
the pro-survival NF-κB pathway (cIAP1/2, XIAP), among
others [10]. In addition, some IAPs can regulate other pro-
cesses involved in cancer, such as cell cycle, cancer-related
inflammation, cell invasion and metastasis [10, 11]. The
expression of IAPs has been studied in several types of
cancer, such as esophageal [12], colon [13], cervical [14]
or prostate [15] cancer.
The aim of the present work was to evaluate the prog-
nostic capability of the tumor expression of a broad
panel of IAPs and caspases for biochemical progression
after radical prostatectomy, as well as to assess its




All the procedures were examined and approved by the
University of Alcalá and Principe de Asturias Hospital
Ethics Committees (PI13/1801; 2013/003/20130214) and
were in accordance with the ethical standards of the
Committee for Human Experimentation, with the Helsinki
Declaration of 1975 (revised in Tokyo 2004) and the
Committee on Publication Ethics guidelines. This study
was performed with the written consent of the patients
or their relatives. All pathological, clinical or personal
data were anonymized and separated from any personal
identifiers. The present study included 84 men who
were diagnosed with prostate cancer and underwent
radical prostatectomy as definitive therapy between
1992 and 1999, without receiving pre-surgical treatment,
or post-surgical therapy before biochemical progression.
Only 40.5 % (n = 34) of patients had biochemical progres-
sion (32 patient at 5 years and 2 patients between 5 and
10 years). In all patients they were studied lymph node
but only six patients are positives. 41.7 % of patients
had positive surgical margins. Prostate cancer was
detected by serum PSA screening and rectal examin-
ation, and diagnostic was confirmed by histopatho-
logical examination of needle biopsy cores. The median
age (range) at the time of surgery was 66 (52–74). Pa-
tients were generally scheduled to have a serum PSA
measure every 3 months for the first year and every
6 months thereafter. Patients with PSA persistence after
radical prostatectomy were included in the study. Me-
dian follow-up (range) time of the cohort was 76.2
(15.6–158.4) months, being defined as the time be-
tween the surgery and the biochemical progression or
the last record. Clinicopathological features of the pa-
tients are shown in Table 1.
Reagents
Total serum PSA was measured by the AxSYM system
(Abbott, IL). The following antibodies were from Santa
Cruz Biotechnology (Santa Cruz, CA): mouse antihuman
caspase-8 (for detection of procaspase-8, used at a 1:25 di-
lution), caspase-8/p20 (cleaved caspase-8, 1:50), caspase-3
(procaspase-3, 1:25), caspase-3/p20 (cleaved caspase-3,
1:100), caspase-7/p20 (caspase-7, 1:25), caspase-9 (procas-
pase-9, 1:50) and Survivin (1:75); rabbit antihuman cIAP2
(1:75) and XIAP (1:100); and goat antihuman cIAP1/2
(1:150) and NAIP (1:100). Biotin-conjugated antibodies
were from Dako (Barcelona, Spain). Avidin-biotin perox-
idase complex (ABC kit) was from Vector Laboratories
(Burlingame, CA).
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Immunohistochemical analysis
Immunohistochemistry was performed following the
avidin-biotin-peroxidase complex (ABC) method as pre-
viously described [15]. Specificity controls for immuno-
histochemistry were as reported previously [5, 15].
Briefly, for negative controls tissues were incubated with
blocking peptides or pre-immune serum (Santa Cruz
Biotechnology). Additionally, in five of the samples, one
part of the prostate tissues was frozen in liquid nitrogen
immediately after surgery and maintained at −80 °C, to
be later used for Western blotting analysis in order to
test antibody specificity. In this portion, cryostat sections
were stained with toluidine blue to confirm the histo-
pathological diagnosis.
Immunostaining in the cancerous epithelium was
evaluated by two independent pathologists (P.M.-O.
and G.O.), blinded for the outcome measure, in five
randomly selected fields per section and six sections
per patient. Patients were stratified as positive (those
showing staining in more than 5 % of the cancerous
epithelium) or negative, as has been previously
described [5, 15].
Statistical analysis
The main outcome measure of the study was time to
biochemical progression at 10 years, defined as the time
between definitive therapy to the first of at least two
consecutive elevations in the total serum PSA level
above 0.2 ng/ml. Established prognostic variables in-
cluded in the study were preoperative serum PSA levels,
pathological and clinical T stages (2010 AJCC/UICC
TNM classification [16]), postoperative Gleason score,
perineural invasion, lymph node involvement, surgical
margin status and overall survival. The pathologists
undertook a regrading of the samples following the 2005
ISUP consensus [17] and the reassigned Gleason scores
were used in the analyses. To evaluate the association
between clinicopathological and immunohistochemical
variables Spearman’s test was performed. Log-rank test
and Kaplan-Meier curves were used for survival compar-
isons. To explore the correlation of the studied immuno-
histochemical parameters and the established prognostic
variables with biochemical progression, univariate and
multivariate Cox proportional hazard regression analyses
were performed. All statistical analyses were performed
using the SPSS 19.0 software (SPSS Inc. Chicago, IL,
USA). P values < 0.05 were considered as significant.
Results
Expression of IAPs and caspases and its correlation with
clinicopathological features
Immunohistochemical analysis revealed a predomin-
antly cytoplasmic expression pattern for all the studied
proteins (Fig. 1). This part has been previously pub-
lished [5, 15]. Table 2 shows the percentage (number)
of patients with positive immunoreactions for the stud-
ied proteins. Spearman’s test evidenced significant posi-
tive correlations between a) cIAP1/2 and pathological T
stage; b) cIAP2 and positive surgical margins; c) Survi-
vin and perineural invasion; d) procaspase-8 and both
clinical and pathological T stages; f ) cleaved caspase-8
and preoperative serum PSA; and g) caspase-7 and
Gleason score and node involvement (Tables 3 and 4).
Moreover, there was a significant inverse correlation
between procaspase-3 and positive surgical margins
(Tables 3 and 4). Interestingly, expression of XIAP,
procaspase-3 and cleaved caspase-3 inversely correlated
with the occurrence of biochemical progression, indi-
cating that these proteins can have a role as prognostic
markers (Tables 3 and 4). Accordingly, the expression
of XIAP and cleaved caspase-3 were positively corre-
lated with overall survival (Tables 3 and 4). On the
other hand, Survivin expression was inversely corre-
lated with overall survival.
Table 1 Clinicopathological features of patients
Median (range)
Age 66 (52–74)
Preoperative serum PSA (ng/ml) 10.3 (0.2-118.0)
% (n)
Preoperative serum PSA
<10 ng/ml 41.7 (35)












Node involvement 7.1 (6)
Positive surgical margins 41.7 (35)
Perineural invasion 17.9 (15)
Total Biochemical progression 40.5 (34)
at 5 years 38.1 (32)
5 - 10 years 2.4 (2)
Survival 64.7a(22)
Deaths 35.3a(12)
aExpressed respect total biochemical progressión
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Univariate analysis for time to biochemical progression of
tumor expression of IAPs and caspases
Differences between the biochemical progression free-
survival times of the groups of patients stratified accord-
ing to tumor expression of IAPs and caspases were ana-
lyzed by the Kaplan-Meier method, using the log-rank
as test for significance. Patients negative for XIAP (Fig. 2)
and, more markedly, for procaspase-3 and cleaved
caspase-3 (Fig. 3) had significantly shorter times to bio-
chemical progression than positive patients.
Univariate Cox proportional hazard regression analysis
confirmed the results obtained in the Kaplan-Meier curves
(Table 5). Of note, patients negative for procaspase-3,
cleaved caspase-3 and, at limit of significance, for XIAP
had a higher risk of progression than positive patients
(Table 5).
Multivariate Cox proportional hazard regression analysis
for time to biochemical progression of XIAP, procaspase-
3, cleaved caspase-3 and classic markers
Finally, we assessed the prognostic capability of the im-
munohistochemical parameters in conjunction with clas-
sic markers. In our series, Gleason score, pathological T
stage and node involvement, but not preoperative PSA,
perineural invasion and positive surgical margins had a
prognostic value for biochemical progression in univari-
ate analysis (Table 6). Gleason score and pathological T
Fig. 1 Expression of IAPs and caspases in prostate cancer tissue. As an example, a negative immunoreaction for XIAP (a) is shown. Positive tumor
immunostaining for cIAP1/2 (b), cIAP2 (c), NAIP (d), Survivin (e), XIAP (f), procaspase-8 (g), cleaved caspase-8 (h), procaspase-3 (i), cleaved caspase-3 (j),
procaspase-9 (k) and caspase-7 (l) is shown. Scale bars: 20 μm (d, f, g, h, j), 25 μm (a, b, e, i, l) and 30 μm (c, k)
Table 2 Percentage (number) of positive patients for IAPs (left
panel) and caspases (right panel)
% (n) % (n)
cIAP1/2 61.90 (52) Procaspase-8 28.57 (24)
cIAP2 33.33 (28) Cleaved caspase-8 48.80 (41)
NAIP 58.33 (49) Procaspase-3 35.71 (30)
Survivin 20.23 (17) Cleaved caspase-3 57.14 (48)
XIAP 35.71 (30) Caspase-7 39.28 (33)
Procaspase-9 38.09 (32)
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stage are two of the most important stablished prog-
nostic factors for prostate cancer [1]. For this reason,
and to prevent an overfitting of the model, only these
two established prognostic factors were introduced in
different multivariate Cox hazard regression models,
along with the immunohistochemical parameters which
resulted significant/borderline significant in the univariate
analyses – i.e. XIAP, procaspase-3 and cleaved caspase-3.
In the multivariate analysis, XIAP (Table 7A), procaspase-3
(Table 7B) and cleaved caspase-3 (Table 7C) remained
as independent prognostic factors after adjusting for
the effects of Gleason score and pathological T stage.
Discussion
In spite of the mounting evidence supporting a predom-
inant pro-tumor role of the IAPs in prostate cancer, in
the present study, according to the Spearman’s test, only
few associations were found between the expression of
these proteins and adverse clinicopathological features.
Thus, significant positive correlations were found between
cIAP1/2 and pathological T stage, cIAP2 and positive sur-
gical margins, and between Survivin and perineural inva-
sion. Furthermore, we found positive correlations between
expression of some caspases and adverse clinicopathologi-
cal features: procaspase-8 correlated with both clinical
and pathological T stages, cleaved caspase-8 correlated
with preoperative serum PSA, and caspase-7 correlated
with Gleason score and the presence of lymph node me-
tastasis. Although at first glance the associations found for
caspases may seem contradictory, some points should be
considered. First, the pro-apoptotic activity of caspases
mostly relies on their cleaved forms and, therefore, higher
levels of procaspases do not necessarily entail enhanced
apoptotic signaling. Further, there are recent evidences
that caspase-8 could exert a pro-tumor role by inducing
cell motility, adhesion and metastasis [18]. In this regard,
Finlay et al. [19] demonstrated that caspase-8 is involved
in the adhesion-mediated activation of the ERK 1/2 signal-
ing pathway. Using caspase-8-null mouse embryo fibro-
blasts, Helfer et al. [20] demonstrated that caspase-8 is
Table 3 Correlation between tumor expression of IAPs and caspases and clinicopahological features
cIAP1/2 cIAP2 NAIP Survivin XIAP
r p r p r p r p r p
Preoperative serum PSA −0.066 0.549 −0.017 0.877 0.069 0.531 0.185 0.091 −0.025 0.228
Pathological T stage 0.219 0.045* 0.019 0.866 0.037 0.735 0.101 0.362 −0.136 0.218
Clinical T stage 0.103 0.349 0.034 0.759 0.118 0.287 0.090 0.414 0.089 0.419
Gleason score 0.153 0.165 −0.124 0.262 0.052 0.641 −0.172 0.118 0.084 0.446
Perineural invasion 0.110 0.320 0.066 0.551 0.079 0.476 0.229 0.036* −0.088 0.426
Node involvement 0.122 0.267 0.000 1.000 0.047 0.672 −0.025 0.824 0.030 0.455
Positive surgical margins 0.066 0.549 0.222 0.042* 0.127 0.251 0.055 0.619 −0.179 0.109
Biochemical progresion −0.002 0.983 0.086 0.438 −0.041 0.711 0.188 0.086 −0.210 0.056
Survival −0.090 0.414 −0.077 0.489 0.119 0.281 0.239 0.019* −0.331 0.002*
Correlations between immunohistochemical variables (according to the stratification shown in Table 2) and preoperative serum PSA, pathological T stage, clinical
T stage and Gleason score were evaluated by Spearman’s test (r, correlation coefficient). *p < 0.05. (Note: significant correlations after Bonferroni correction should
be those with a p < 0.005)
Table 4 Correlation between tumor expression of IAPs and caspases and clinicopahological features
Procaspase-8 Cleaved caspase-8 Procaspase-3 Cleaved caspase-3 Caspase-7 Procaspase-9
r p r p r p r p r p r p
Preoperative serum PSA 0.000 1.000 0.294 0.007* 0.076 0.494 −0.098 0.377 0.185 0.091 0.017 0.881
Pathological T stage 0.216 0.048* −0.056 0.611 −0.154 0.161 0.160 0.146 −0.023 0.833 −0.072 0.513
Clinical T stage 0.235 0.031* −0.003 0.979 −0.161 0.144 −0.055 0.617 0.121 0.237 −0.054 0.625
Gleason score 0.118 0.287 −0.006 0.954 0.013 0.904 0.107 0.331 0.289 0.008* −0.151 0.171
Perineural invasion 0.118 0.285 0.104 0.345 −0.023 0.834 0.027 0.808 0.007 0.951 −0.046 0.680
Node involvement −0.175 0.110 0.007 0.952 −0.110 0.318 0.147 0.183 0.250 0.022* 0.068 0.539
Positive surgical margins 0.160 0.145 −0.149 0.176 −0.277 0.011* −0.098 0.377 −0.037 0.738 0.133 0.229
Biochemical progresion 0.015 0.890 −0.126 0.254 −0.362 0.001* −0.364 0.001* 0.082 0.461 0.002 0.983
Survival 0.163 0.139 0.014 0.898 −0.161 0.142 −0.250 0.022* −0.202 0.065 −0.133 0.229
Correlations between immunohistochemical variables (according to the stratification shown in Table 2) and preoperative serum PSA, pathological T stage, clinical
T stage and Gleason score were evaluated by Spearman’s test (r, correlation coefficient). *p < 0.05. (Note: significant correlations after Bonferroni correction should
be those with a p < 0.005)
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able to promote cell motility and calpain activity under
non apoptotic conditions. Interestingly, it has been shown
that the role of caspase-8 on cell motility, adhesion and
metastasis is independent of the caspase catalytic activity
and has been linked to the phosphorylation of procaspase-
8 on tyrosine 380, which prevents its cleavage [20]. In
addition to these pro-tumor roles of caspase-8, cells with
impaired apoptosis despite displaying continued caspase
activation have been shown to secrete mitogenic signals in
a manner which is dependent on the catalytic activity of
caspases [21]. The persistence of these cells could result in
increased proliferation of the neighbor cells and, conse-
quently, promote tumor progression [21]. These less-
known functions of caspases could also explain why
higher expression levels of some of them have been
correlated with a poor prognosis in some cancers [22, 23].
All these pro-tumor activities of caspases should be taken
into account in future research.
In the present work, we also found that patients with
positive immunostaining for XIAP had a significantly bet-
ter prognosis compared to negative patients. This result is
not surprising, as higher XIAP expression has been re-
ported as a favorable prognostic factor in other cancers
[24, 25]. Interestingly, it has been shown that TRAMP
(transgenic adenocarcinoma of the mouse prostate) mice
deficient in XIAP tend to have a more aggressive disease
[26]. In addition, our results are in agreement with a study
by Seligson et al. [27] in which higher XIAP expression
was also a favorable prognostic factor for biochemical pro-
gression after radical prostatectomy. Of note, in that study,
Fig. 2 Kaplan-Meier curves for time to biochemical progression according to tumor expression of IAPs. Vertical tick marks represent censored
observations. Statistical significance was evaluated by log-rank test (p values). Bold value indicates statistical significance
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Fig. 3 Kaplan-Meier curves for time to biochemical progression according to tumor expression of caspases. Vertical tick marks represent censored
observations. Statistical significance was evaluated by log-rank test (p values). Bold values indicate statistical significance
Table 5 Univariate Cox proportional hazard regression analysis for time to biochemical progression according to tumor expression
of IAPs and caspases
p HR (95 % CI) p HR (95 % CI)
cIAP1/2 0.931 0.970 (0.485-1.938) Procaspase-8 0.962 1.018 (0.487-2.129)
cIAP2 0.646 1.176 (0.588-2.351) Cleaved caspase-8 0.222 0.653 (0.330-1.294)
NAIP 0.543 0.811 (0.412-1.596) Procaspase-3 0.005* 0.260 (0.100-0.672)
Survivin 0.108 1.831 (0.875-3.834) Cleaved caspase-3 0.002* 0.327 (0.161-0.662)
XIAP 0.055 0.460 (0.208-1.016) Caspase-7 0.435 1.310 (0.665-2.579)
Procaspase-9 0.936 1.029 (0.515-2.055)
Abbreviations: CI confidence interval, HR hazard ratio. Bold values indicate statistical significance. *p < 0.05
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despite taking different methodological approaches – re-
garding the used antibody, the immunostaining scoring and
the stratification criteria – XIAP added prognostic value to
Gleason score and tumor extension [27], in accordance
with the results derived from our multivariate analysis.
Therefore, our results add support to previous findings that
XIAP may be useful as a predictor of prostate cancer pro-
gression, which strongly warrants validation in large pro-
spective studies.
In addition to observations derived from functional
studies, the fact that XIAP expression positively associ-
ates with a favorable prognosis in some cancers has led
to question the pro-tumor role of this IAP. Some au-
thors have argued that this controversy could lie in the
initial studies on the anti-apoptotic role of XIAP, which
are based on its overexpression in cell lines and the
short-term response to different pro-apoptotic stimuli
[28]. Thus, when XIAP is stably overexpressed in cell
lines at levels comparable to those of tumor cells, it does
not protect from apoptosis induced by commonly used
chemotherapeutic agents [28]. It has even been recently
demonstrated that XIAP is able to mediate cell death
through mitochondrial outer membrane permeabilization
upon cell detachment [29] or stimulation with resvera-
trol [30]. It is likely that XIAP functions as an anti- or
pro-apoptotic factor, or that is neutral, depending on
the scenario. More studies are needed to elucidate the
mechanisms accounting for its possible anti-tumor role
in patients and its potential as a therapeutic target.
The existing studies on the predictive value of cas-
pases in prostate cancer have focused on assessing the
association between the presence of allelic variants of
genes encoding for these proteins and the risk of dis-
ease or the response to therapy [31, 32]. In the present
work, we found that negative expression of either
procaspase-3 or cleaved caspase-3 strongly associated
with an earlier biochemical progression. As demon-
strated in the multivariate Cox models, the prognostic
capability of both caspase-3 forms was independent on
established prognostic factors – Gleason score and
pathological T stage – indicating that they may help to
identify patients at high risk of progression. Among the
executioner caspases, caspase-3 is thought to be the
most determinant in integrating the pro-apoptotic sig-
nals coming from both extrinsic and the intrinsic path-
ways, and ultimately, in triggering the activation of the
apoptotic program [3]. Therefore, it is tentative to
speculate from our observations that suppression of
caspase-3 expression profoundly enhances the survival
capability of prostate cancer cells, thus contributing to
prostate cancer progression. Strategies aimed to restore
or enhance expression of caspases, such as the use of
either demethylating agents [33] or the adenovirus-
mediated transfer of inducible caspases [34], may be
effective for prostate cancer treatment, particularly in
those patients lacking tumor caspase-3 expression.
Conclusions
In summary, we found that tumor expression of cIAP1/
2, cIAP2, Survivin, procaspase-8, cleaved caspase-8,
procaspase-3 and caspase-7 expression correlates with
clinicopathological features of prostate cancer, indicating
that these proteins may constitute markers of local dis-
ease. Moreover, negative tumor expression of XIAP,
procaspase-3 or cleaved caspase-3 predicted early bio-
chemical progression after radical prostatectomy, both
alone and after adjusting for the effects of Gleason score
and pathological T stage. This adds significance to a
previous study evaluating the prognostic capability of
XIAP in prostate cancer and others indicating an anti-
tumor role for this IAP. Our findings also support the
idea that loss of caspase-3 expression in prostate cancer
cells strongly decreases their sensitivity to apoptosis,
thus contributing to prostate cancer progression. XIAP,
procaspase-3 and cleaved caspase-3 may improve the
Table 6 Univariate Cox proportional hazard regression analysis
for time to biochemical progression according to
clinicopathological features
p HR (95 % CI)
Preoperative serum PSA 0.199 1.602 (0.780-3.287)
Pathological T stage 0.006* 2.155 (1.253-3.706)
Gleason score 0.016* 1.816 (1.118-2.949)
Perineural Invasion 0.259 1.579 (0.715-3.489)
Node involvement 0.000* 5.053 (2.039-12.518)
Positive surgical margins 0.374 1.357 (0.692-2.661)
Abbreviations: CI confidence interval, HR hazard ratio. Bold values indicate
statistical significance. *p < 0.05
Table 7 Multivariate Cox proportional hazard regression analysis
for time to biochemical progression of XIAP, procaspase-3 and
cleaved caspase-3
A p HR (95 % CI)
Gleason score 0.023* 1.781 (1.083-2.928)
Pathological T stage 0.035* 1.805 (1.042-3.128)
XIAP 0.042* 0.436 (0.196-0.971)
B p HR (95 % CI)
Gleason score 0.020* 1.847 (1.104-3.091)
Pathological T stage 0.176 1.470 (0.842-2.568)
Procaspase-3 0.009* 0.268 (0.100-0.718)
C p HR (95 % CI)
Gleason score 0.007* 2.093 (1.220-3.592)
Pathological T stage 0.001* 2.557 (1.441-4.537)
Cleaved caspase-3 0.000* 0.213 (0.099-0.458)
Abbreviations: CI confidence interval, HR hazard ratio. *p < 0.05
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accuracy of the existing markers to predict biochemical
progression after radical prostatectomy. Prospective
studies in larger cohorts of patients are needed to con-
firm their prognostic utility.
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